These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Author: Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB.
    Journal: Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972.
    Abstract:
    AIM: The aim of this study was to evaluate the prognostic value of the serum CA-125 level for complete responders after 6 cycles of primary adjuvant paclitaxel/carboplatin chemotherapy in advanced epithelial ovarian cancer. PATIENTS AND METHODS: The clinical data of 123 complete responders after 6 cycles of primary adjuvant paclitaxel/carboplatin chemotherapy for epithelial ovarian cancer FIGO stages III and IV were collected between January 1997 and March 2007. All patients were divided into 3 groups according to the serum CA-125 level after 6 cycles of the chemotherapy: group I (< 10 U/ml), group II (10-21 U/ml), and group III (> 21 U/ml). The effect of the serum CA-125 level on survival was evaluated using the Kaplan-Meier method and Cox proportional hazard analysis. RESULTS: The median progression-free survival was 26, 14, and 10 months, and the median overall survival was 105, 42, and 37 months in groups I, II, and III, respectively (p < 0.05). The lower serum CA-125 level and optimal debulking surgery were prognostic factors for improving survival (p < 0.05). CONCLUSION: The serum CA-125 level after 6 cycles of primary adjuvant paclitaxel/carboplatin chemotherapy may be a good prognostic factor for survival in complete responders after 6 cycles of chemotherapy in advanced epithelial ovarian cancer.
    [Abstract] [Full Text] [Related] [New Search]